Adipo Therapeutics
ActiveAdipo Therapeutic is a biotechnology company that is developing a novel asset for the treatment of obesity by increasing energy expenditure via mitochondria biogenesis and activation in white adipose tissue (fat browning).
What it does
Adipo Therapeutics is a biotechnology company developing innovative treatments for obesity and metabolic diseases by increasing energy expenditure through mitochondrial biogenesis and activation in white adipose tissue. The company’s novel approach utilizes Notch-inhibiting nanoparticles to induce the conversion of energy-storing white fat into metabolically active brown fat, promoting weight loss without the need for calorie restriction. This strategy addresses limitations of traditional weight loss methods that often reduce resting metabolic rate. Preclinical and ex-vivo human tissue studies have demonstrated promising outcomes, including weight reduction and improved blood glucose and lipid regulation. By pioneering fat browning technology, Adipo Therapeutics contributes to advancing metabolic disease treatment and offers a potential new paradigm in obesity management.
Its site says now · captured 2026-08-26
Adipo Therapeutics | Innovative Biotechnology | Indianapolis, IN
Adipo Therapeutics is a biotech company advancing the treatment of obesity by increasing energy expenditure through increasing metabolically beneficial brown fat using a 1st in class and novel MOA of Notch-inhibiting nanoparticles.
Next to it in Healthcare and bio · Obesity therapeutics via fat browning
- Bahto BiosciencesPlug and Play PnP 2026
Bahto Biosciences develops non-opioid small-molecule therapeutics for painful peripheral neuropathy, a condition with limited effective treatment options that afflicts more than 19 million Americans.
- Cryton BiosciencesPlug and Play PnP 2026
Cryton Biosciences is developing a first-in-class dual-action drug that restores mitochondrial function in immune AND cancer cells resulting in tumor death.
- Diapin TherapeuticsPlug and Play PnP 2026
Novel Therapies for Cardiovascular and Metabolic Diseases
- RNARevivePlug and Play PnP 2026
RNARevive is developing a next-generation RNA platform that enables long-lasting, low-dose protein therapeutics. Our lead candidates tackle the anti-aging and longevity space, targeting osteoporosis, age-related macular degeneration (AMD), and liver diseases.
- FinalDoseY Combinator X26
Programmable DNA drug destroying all cancers, unlocking 80% of targets
- Scioto BiosciencesPlug and Play PnP 2025
Scioto is a preclinical stage company developing innovative therapies devoted to having a transformative impact.
- Eris BiotechY Combinator W24
Our drugs engage the immune system to fight tumors
- SynsoryBioY Combinator W24
"If-then" conditional logic for protein drugs